Last checked at 7 Nov 2019 12:45
Ovoca Bio plc
("Ovoca" or the "Company")
Attendance at BIO-Europe Conference
Dublin, Ireland, November 7, 2019 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, today announces that the Company will be attending the 25th annual BIO-Europe Partnering Conference, taking place from 11-13 November 2019, in Hamburg, Germany.
Management will host one-on-one meetings with investors at the Conference. To inquire about arranging a meeting with management, please contact Dr Daniel Nemenov, at Ovoca Bio.
For further information:
Ovoca Bio plc
Kirill Golovanov (Chief Executive)
Tel +353 1 661 9819
info@ovocabio.com
Davy (Nominated Adviser, Euronext Growth Advisor and Broker)
John Frain / Daragh O'Reilly
Tel: +353 1 679 6363
Consilium Strategic Communications
Chris Gardner, Chris Welsh, Carina Jurs
ovocabio@consilium-comms.com
Tel: +44 (0)20 3709 5700
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million premenopausal women in the US alone.
The Company's lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.
Ovoca Bio has filed for approval for the marketing of BP-101 in Russia and is seeking to develop the drug for major global markets - in particular the United States and Europe.